evipedia.ai
← Back

NAD+ for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Nicotinamide Adenine Dinucleotide, NAD, NAD⁺, Coenzyme I, Diphosphopyridine Nucleotide, DPN

Motivation

NAD+ (nicotinamide adenine dinucleotide) is a small molecule that every cell uses to turn food into usable energy and to power the machinery that repairs damaged DNA. Laboratory work has tied lower cellular NAD+ to many of the changes that come with age, and animals given the raw materials to rebuild it often look metabolically younger.

Because NAD+ itself is broken apart before it can enter a cell, people who want more of it swallow one of its raw materials — usually nicotinamide riboside or nicotinamide mononucleotide — or take niacin, a long-known form of vitamin B3. Others pay clinics to infuse NAD+ into a vein. A large consumer market grew up around these products well ahead of the human evidence, and even the starting assumption — that NAD+ falls as people age — is now disputed.

This review examines what raising NAD+ does in people. It looks at how the molecule works, what the human trials report on benefit and harm, how the various forms are dosed and sourced, who has funded the research, and where the findings disagree.

Benefits - Risks - Protocol - Conclusion

High-level overviews of NAD+ and its raw materials from independent analysts, longevity researchers, and consumer-facing science publications.

  • Does NMN improve metabolic health in humans? - Peter Attia

    A sceptical read of the first efficacy trial of nicotinamide mononucleotide (NMN) that also explains why intravenous NAD+ is unlikely to reach cells and why the mouse lifespan record leaves the case unproven.

  • NAD+ in Aging: Role of Nicotinamide Riboside and Nicotinamide Mononucleotide - Rhonda Patrick

    A long-form solo episode covering NAD+ biosynthesis routes, why NAD+ cannot be supplemented directly, how the salvage pathway (the recycling route that supplies most NAD+) works, and the theoretical cancer-growth concern.

  • RHR: How to Slow Aging and Increase Healthspan, with Dr. David Sinclair - Chris Kresser

    A freely readable transcript with a headed NAD+ section in which Sinclair explains why sirtuins (enzymes that run on NAD+) motivate raising it, and discloses on air his stake in these products.

  • NYC Woman Dead After Receiving a “Longevity Infusion” - Arkadi Mazin

    Reports a fatality after an intravenous NAD+ infusion at an unlicensed clinic, with longevity researchers commenting on preparation, sourcing and quality-control risks specific to unregulated infusion practice.

  • What is NAD+? - Laurie Mathena

    An accessible primer on NAD+ chemistry, sirtuins and the main raw materials. Life Extension sells NAD+ products, so the framing is favourable and the caveats are thinner than elsewhere.

All six priority platforms carry relevant material, but only five items may be listed, so no separate item from Andrew Huberman appears above. His solo treatment is an Ask Me Anything episode readable only behind Huberman Lab Premium, and his two freely readable dedicated episodes are both guest interviews whose guests are already represented above — Peter Attia under his own name, and David Sinclair through the Chris Kresser transcript.

Grokipedia

Nicotinamide adenine dinucleotide

A fact-checked encyclopedia entry covering NAD+ chemistry and biosynthesis routes, the evidence that levels decline with age, and the human record for raising it with precursors or intravenous infusion.

Examine

Nicotinamide Adenine Dinucleotide

Examine’s independent supplement page, categorised under Healthy Aging & Longevity, summarising how NAD+ helps enzymes work, why levels are said to fall with age, and whether NADH (its reduced form) capsules raise it.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

Independent laboratory testing of NAD+, NADH, nicotinamide riboside and nicotinamide mononucleotide products, documenting widespread label-claim failures, counterfeits, and shifting regulatory status. ConsumerLab sells subscriptions and a certification seal.

Systematic Reviews

Systematic reviews and meta-analyses of human trials of NAD+ and its raw materials, covering both claimed benefits and safety.

The principal long-term risk of raising NAD+ — accelerating an existing cancer — is unrepresented: no systematic review or meta-analysis of that question in humans exists, because no trial has followed users long enough to measure cancer incidence.

Mechanism of Action

NAD+ is a coenzyme (a helper molecule an enzyme needs to function). It ferries electrons through the reactions that convert food into energy, and it is also destroyed as a raw material by three enzyme families: sirtuins (proteins linked to stress resistance), PARPs (poly-ADP-ribose polymerases, which repair broken DNA), and CD38 (an immune-cell enzyme that degrades NAD+ and becomes more active with age). Because these enzymes consume rather than recycle it, cells must resynthesise NAD+ continuously.

Three supply routes exist. The de novo route builds NAD+ from the amino acid tryptophan. The Preiss–Handler route uses niacin via NAPRT (nicotinic acid phosphoribosyltransferase, which converts niacin toward NAD+). The salvage route dominates, recycling nicotinamide through NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of that recycling). Oral nicotinamide riboside and nicotinamide mononucleotide feed this route; mononucleotide is largely stripped of its phosphate to riboside before absorption, and riboside is re-phosphorylated inside cells by NMRK1 and NMRK2 (nicotinamide riboside kinases, which activate it).

Pharmacologically, oral riboside peaks in plasma within one to two hours with a half-life of a few hours, while whole-blood NAD+ rises over roughly two weeks and then plateaus. Uptake is highest in liver, blood and gut and lowest in brain and muscle. Clearance is by methylation via NNMT (nicotinamide N-methyltransferase, which tags surplus nicotinamide for excretion), not by the drug-metabolising cytochrome P450 enzymes.

A competing explanation holds that healthy adults are not precursor-limited at all, so extra substrate raises measurable blood NAD+ without altering tissue function.

Historical Context & Evolution

NAD+ was discovered in 1906 by Arthur Harden and William Young as a heat-stable “cozymase” that yeast extract needed to ferment sugar, and it was characterised chemically in the 1930s by Otto Warburg and by Conrad Elvehjem, whose work identified nicotinic acid as the anti-pellagra factor. Its original therapeutic use was therefore nutritional: gram doses of niacin cured pellagra, a deficiency disease of the skin, gut and nervous system. From the 1950s onward niacin acquired a second, pharmacological use as a lipid-lowering agent at doses far above nutritional need.

Interest in NAD+ as a longevity target grew from sirtuin biology in the late 1990s and 2000s, when work in yeast and mice showed that these enzymes require NAD+ and that their activity tracks nutrient availability. Reports that tissue NAD+ falls with age, and that restoring it in old mice improves mitochondrial function, muscle performance and blood-vessel behaviour, converted a vitamin into a candidate for slowing ageing.

Two developments have since reshaped the picture rather than closing it. Large lipid trials showed that gram-dose niacin carried real harm without cardiovascular benefit, and careful mass-spectrometry work has questioned whether blood NAD+ declines with age at all. Neither result addresses tissue NAD+ directly, so the founding premise remains open rather than settled in either direction.

Expected Benefits

High 🟩 🟩 🟩

Modest Reduction in Diastolic Blood Pressure

Raising NAD+ lowers resting diastolic pressure slightly, probably by improving the blood vessel lining’s ability to relax. A meta-analysis of ten randomized controlled trials (RCTs — studies in which participants are assigned to treatment or placebo by chance) in 349 adults found a fall in diastolic pressure, with systolic pressure falling only in those aged 60 and over; an independent safety meta-analysis found the same direction. For a proactive adult already at optimal pressure the expected gain is negligible; the signal concentrates in older people with elevated readings.

Magnitude: Diastolic pressure −2.15 mmHg (95% confidence interval, or CI — the range within which the true value most likely lies: −3.68 to −0.61); systolic pressure −3.94 mmHg (95% CI −7.06 to −0.82) in participants aged 60 and over, and not significantly changed overall.

Medium 🟩 🟩

Fewer New Non-Melanoma Skin Cancers with Nicotinamide

Nicotinamide, the cheapest NAD+ raw material, restores the energy supply that skin cells need to repair ultraviolet damage. In a phase 3 RCT in 386 adults with at least two prior skin cancers, 500 mg twice daily cut the rate of new basal-cell and squamous-cell carcinomas over twelve months, with actinic keratoses (rough pre-cancerous patches) also reduced. The benefit vanished once treatment stopped. A later trial in organ-transplant recipients found no reduction, so the effect appears confined to people with intact immune function.

Magnitude: 23% lower rate of new non-melanoma skin cancers at 12 months (95% CI 4% to 38%); actinic keratoses 13% lower at 12 months.

Improved Walking Distance in Peripheral Artery Disease ⚠️ Conflicted

Peripheral artery disease (narrowed leg arteries that limit walking) involves impaired mitochondrial function in leg muscle, which NAD+ supports. In the NICE randomized trial in 90 participants, six months of nicotinamide riboside improved six-minute walk distance against placebo, most in those taking at least three-quarters of their capsules; resveratrol added nothing. An 80-participant manufacturer-run trial also lengthened walking distance, but a meta-analysis in adults over 60 found no effect on muscle index, grip strength or gait speed. Net reading: outside leg-artery disease, the walking gain is not independently reproducible.

Magnitude: +17.6 metres in six-minute walk distance versus placebo in peripheral artery disease (90% CI +1.8 to +∞); +31.0 metres among participants taking at least 75% of study capsules; pooled independent estimates in adults over 60 cross zero (gait speed mean difference −0.01 m/s, 95% CI −0.08 to 0.06).

Increased Muscle Insulin Sensitivity in Prediabetes

Muscle insulin sensitivity is how readily muscle takes up glucose when insulin is present. In a ten-week RCT in 25 postmenopausal women who were overweight or obese and prediabetic, 250 mg of nicotinamide mononucleotide daily raised clamp-measured muscle glucose disposal and muscle insulin signalling, while placebo did not. Liver and fat-tissue insulin sensitivity, body weight and blood pressure were unchanged, and pooled analyses of broader metabolic markers have been null. The trial was small and the finding has not been replicated.

Magnitude: Roughly a 25% relative increase in insulin-stimulated muscle glucose disposal; no change in fasting glucose, glycated haemoglobin or lipids.

Low 🟩

Reduced Daytime Drowsiness and Fatigue

In a twelve-week trial in 108 older Japanese adults, 250 mg of nicotinamide mononucleotide taken in the afternoon reduced self-rated drowsiness more than morning dosing or placebo. Sleep quality did not change. The fatigue scale is not widely validated, and the ingredient supplier co-authored the study.

Magnitude: Effect size 0.64 for drowsiness and 0.72 for chair-stand time in the afternoon-dosing group.

Improved Inner Retinal Function in Glaucoma

Retinal ganglion cells in glaucoma show mitochondrial vulnerability that NAD+ may buffer. In a crossover RCT in 57 patients, high-dose nicotinamide improved an electrical measure of inner retinal nerve function. Visual field loss, the endpoint that matters, showed only a trend over the short trial.

Magnitude: The electrical retinal measure improved beyond the repeatability threshold in 23% of participants on nicotinamide versus 9% on placebo, with an overall rise of 14.8% (95% CI 2.8% to 26.9%).

Cognitive Function in Mild Cognitive Impairment ⚠️ Conflicted

Three placebo-controlled trials of nicotinamide riboside in older adults with mild cognitive impairment (memory or thinking problems beyond normal ageing but short of dementia) have reported stable cognitive scores, mixed biomarker changes and no clinical improvement. Net reading: NAD+ rises reliably, cognition does not follow.

Magnitude: No change in global cognitive scores across three trials; the literature reports no positive outcome figure for cognition.

Speculative 🟨

Lifespan Extension

The founding claim rests on rodent work. Nicotinamide riboside failed to extend lifespan in either sex in the National Institute on Aging’s testing programme, while single-laboratory mouse studies reported gains. No human data exist.

Lower Circulating Inflammatory Markers

A three-week trial in aged men found an anti-inflammatory gene signature in muscle and lower circulating cytokines after nicotinamide riboside. These are unvalidated biomarkers with no accompanying clinical endpoint.

Reduction in Epigenetic Age

An exploratory analysis within a small mild-cognitive-impairment trial found modestly increased DNA methylation and lower estimated epigenetic age. The measure is an unvalidated ageing clock and the comparison was not corrected for multiple testing.

Benefit-Modifying Factors

  • NMRK1 and NAPRT expression: The kinases that activate nicotinamide riboside and the enzyme that handles niacin are unevenly expressed across tissues. Low expression in brain and skeletal muscle plausibly explains why blood NAD+ rises while muscle and cognitive endpoints often do not.

  • Baseline NAD+ and inflammatory status: People with genuinely depleted NAD+ — through chronic inflammation, heavy alcohol use, or disease — have more headroom to gain. In healthy, well-nourished adults the salvage pathway is probably not substrate-limited, which caps any achievable benefit.

  • Baseline blood pressure: The blood-pressure effect is concentrated in those with elevated readings; participants starting in the optimal range showed little movement. Similarly, muscle insulin sensitivity improved in prediabetes but broader metabolic markers did not shift in metabolically healthy volunteers.

  • Sex: The trials are largely single-sex — the insulin-sensitivity trial enrolled only postmenopausal women, the muscle-biopsy trial only aged men — so no direct comparison exists. Sex-specific benefit estimates for NAD+ raising are currently unavailable rather than absent.

  • Age and pre-existing conditions: Every positive functional result comes from adults aged roughly 55 to 80, or from disease populations such as peripheral artery disease, prediabetes and glaucoma. Benefit demonstrated in a diseased 70-year-old should not be assumed in a healthy 45-year-old.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Flushing and Itching with Gram-Dose Nicotinic Acid

Nicotinic acid triggers prostaglandin release in skin, producing intense facial and upper-body flushing, warmth and itching within thirty minutes of a dose. It is dose-dependent, worsened by alcohol and hot drinks, and partially blunted by aspirin or extended-release formulations. In the 25,673-participant HPS2-THRIVE trial even a run-in period designed to exclude intolerant people did not eliminate it. Nicotinamide, nicotinamide riboside and nicotinamide mononucleotide do not cause flushing — dose-ranging riboside trials, run by the ingredient’s patent holder ChromaDex, reported none.

Magnitude: Flushing affects the large majority of gram-dose nicotinic acid users; skin-related serious adverse events occurred in absolute excess of 0.3 percentage points over placebo in HPS2-THRIVE.

Serious Adverse Events with Gram-Dose Nicotinic Acid

At two grams daily, HPS2-THRIVE found no reduction in major vascular events but clear excesses of serious harm across several organ systems, including loss of diabetes control, new diabetes diagnoses, gastrointestinal and musculoskeletal events, infection and bleeding. A Cochrane review of 23 niacin trials found no benefit and double the discontinuation rate for side effects. This applies to lipid-lowering nicotinic acid, not to the milligram doses of riboside or mononucleotide used for NAD+ purposes — but it remains the only long-term controlled safety dataset for any NAD+ raw material.

Magnitude: Absolute excess over placebo across 3.9 years: serious diabetes disturbance 3.7 percentage points, new diabetes 1.3, infection 1.4, gastrointestinal 1.0, musculoskeletal 0.7, bleeding 0.7.

Medium 🟥 🟥

Cardiovascular Risk Signal from Excess Niacin Breakdown Products

When intake of any NAD+ raw material exceeds what the body can use, the surplus is methylated and excreted as 2PY and 4PY (two pyridone metabolites). Metabolomic work across three cohorts totalling over 4,000 cardiac patients found that higher blood levels of these end-products predicted major heart events over three years, and 4PY induced vessel-wall adhesion molecules and immune cells sticking in mice. The cohorts were high-risk cardiac patients, not supplement users, and no trial has tested whether riboside or mononucleotide dosing raises these metabolites enough to matter.

Magnitude: Adjusted hazard ratios (how much more often an event occurs in one group than another over the follow-up) for major adverse cardiovascular events in the top versus bottom quartile: 1.64 and 2.02 for 2PY, 1.89 and 1.99 for 4PY across two validation cohorts.

Mild Gastrointestinal and Neurological Symptoms with Oral Precursors

Nausea, bloating, loose stools, headache and muscle discomfort are the symptoms most often logged in oral riboside and mononucleotide trials. A meta-analysis of fifteen trials at 250–2000 mg daily for up to 24 weeks found no excess of overall, serious, or system-specific adverse events versus placebo, and no rise in liver enzymes. Eight-week dose-ranging work at up to 1000 mg reached the same conclusion. The symptoms are real but occur at placebo rates; the follow-up nowhere exceeds six months.

Magnitude: No statistically significant difference from placebo in overall adverse events, withdrawals for adverse events, or alanine and aspartate aminotransferase (liver enzymes) across pooled trials.

Liver Enzyme Elevation at Gram-Level Doses

Sustained-release nicotinic acid raises transaminases (liver enzymes) and can cause hepatitis. In a dose-escalation trial, 52% of patients on sustained-release niacin at three grams daily developed hepatotoxicity, against none on the immediate-release form. Nicotinamide at three grams daily and riboside to one gram have not shown this.

Magnitude: 52% hepatotoxicity on sustained-release niacin escalated to 3 g/day versus none on the immediate-release form; liver enzymes were unchanged at riboside and mononucleotide doses of 250–2000 mg/day.

Low 🟥

Infusion Reactions with Intravenous NAD+

A retrospective review of a commercial infusion clinic found that 500 mg of intravenous NAD+ produced moderate-to-severe gastrointestinal symptoms, raised heart rate and chest pressure during infusion, forcing the infusion rate down; nicotinamide riboside given the same way caused only mild tingling and cramping. Symptoms resolved on completion.

Magnitude: Mean infusion time 97 minutes for NAD+ versus 37 minutes for riboside, the difference driven by symptom-forced rate reduction.

Unregulated Infusion Practice

Intravenous NAD+ is administered largely outside medical oversight, and a systematic review found no outcome trial of the route at all. A 2026 report describes a fatality after an infusion by an unlicensed operator, with the cause — active ingredient, contamination, preparation or administration — still undetermined pending the medical examiner.

Magnitude: Not quantified in available studies. No registry or controlled trial tracks adverse events from commercial infusion practice, so only individual case reports exist.

Reduced Cerebral Blood Flow in the Default Mode Network

A ten-week trial in twenty adults with mild cognitive impairment found lower blood flow in the brain’s default mode network (the regions most active at rest) on nicotinamide riboside, largest in the left inferior parietal lobe. The authors note the finding would not survive correction for multiple comparisons.

Magnitude: Between-group difference of 0.92 standard units for the network overall and 1.66 for the left inferior parietal lobe, in a single 20-person trial.

Sleep Disruption with Late-Day Dosing

Users commonly report alerting effects and difficulty falling asleep when raw materials are taken in the evening. The only timing-controlled trial dosed in the afternoon rather than at night and found reduced drowsiness with unchanged sleep quality, so the evening effect rests on user report alone.

Magnitude: Not quantified in available studies. No trial has dosed in the evening and measured sleep, so only self-reported accounts exist.

Speculative 🟨

Acceleration of an Existing Cancer

Tumours are metabolically dependent on NAD+, and imaging work in mice linked nicotinamide riboside uptake to increased metastasis in an aggressive breast cancer model. No human study has measured cancer incidence or progression in users.

Kidney Injury with Prolonged High-Dose Use

Laboratory work in aged rodents suggests long-term nicotinamide mononucleotide may injure kidney tissue. No human trial has run long enough to test this; pooled human data show no change in creatinine or urea.

Methyl-Group Depletion

Clearing surplus nicotinamide consumes methyl groups, raising a theoretical concern about depleting one-carbon metabolism — the body’s methyl-group supply. Controlled dosing to one gram daily did not dysregulate it, so this remains mechanistic rather than observed.

Risk-Modifying Factors

  • NNMT activity: Nicotinamide N-methyltransferase clears surplus nicotinamide by attaching a methyl group. High activity increases production of the 2PY and 4PY end-products linked to vascular inflammation; low activity raises free nicotinamide, which inhibits sirtuins.

  • Baseline biomarkers: Elevated liver enzymes, glycated haemoglobin, uric acid or fasting glucose before starting mark the people most likely to be pushed over a threshold by gram-dose nicotinic acid, whose harms cluster in exactly those systems.

  • Sex: Trials have been small and frequently single-sex, so no sex-specific safety estimate exists for nicotinamide riboside or mononucleotide. Reported flushing intensity with nicotinic acid is greater in women, but this comes from lipid trials rather than NAD+ dosing.

  • Pre-existing conditions: Active or recent malignancy, poorly controlled type 2 diabetes, gout, liver disease, bleeding disorders and advanced kidney disease each map onto a documented harm of the gram-dose nicotinic acid route or an unresolved theoretical concern.

  • Age: Older adults carry more undiagnosed malignancy, more polypharmacy and lower renal clearance. They are also the group in which every positive trial was run, so risk and benefit both concentrate at the older end of the target range.

Key Interactions & Contraindications

  • Statins (atorvastatin, simvastatin, rosuvastatin): Caution with gram-dose nicotinic acid — additive muscle toxicity, with rhabdomyolysis (severe muscle breakdown) reported. Monitor creatine kinase, a muscle-damage enzyme, if muscle pain develops; the risk is not shared by riboside or mononucleotide.

  • Blood-pressure medicines (angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers): Caution — additive lowering, and nicotinic acid adds blood-vessel-widening flushing. Consequence is symptomatic hypotension (dizziness on standing). Separate dosing by several hours and recheck pressure after two weeks.

  • Glucose-lowering drugs (metformin, sulfonylureas, insulin): Caution with gram-dose nicotinic acid, which worsens glycaemic control and precipitates new diabetes. Monitor fasting glucose and glycated haemoglobin at 6 and 12 weeks, and adjust the diabetes regimen rather than stopping monitoring.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Caution — gram-dose nicotinic acid produced an absolute excess of serious bleeding in a large outcome trial. Consequence is serious bleeding. No such signal exists for riboside or mononucleotide.

  • Anticonvulsants (carbamazepine, primidone): Caution — nicotinamide at gram doses can slow their clearance and raise serum levels, causing sedation, unsteadiness and double vision. Check drug levels within two weeks of starting or changing dose.

  • Uric-acid-lowering drugs (allopurinol, febuxostat): Caution — nicotinic acid competes with uric acid for excretion by the kidney and can trigger gout flares. Consequence is acute arthritis. Monitor uric acid and avoid the nicotinic acid route in people with gout.

  • PARP inhibitors (olaparib, niraparib) and NAMPT-targeting oncology agents: Absolute contraindication during therapy — these drugs work by depleting tumour NAD+, and supplying the substrate is expected to antagonise them. Consequence is loss of anticancer effect.

  • Over-the-counter analgesics (aspirin, ibuprofen, paracetamol): No caution required — aspirin 325 mg taken 30 minutes before nicotinic acid blunts flushing, a deliberately additive use. Paracetamol and ibuprofen have no known interaction with any NAD+ raw material.

  • Other vitamin B3 forms taken together: Caution — stacking riboside, mononucleotide, nicotinamide and a B-complex multiplies total niacin equivalents beyond tolerable upper intake. Consequence is unnecessary methyl-group consumption. Count all sources before choosing a dose.

  • CD38-inhibiting supplements (apigenin, quercetin, luteolin): Additive by design — these slow NAD+ degradation while precursors raise supply. Consequence is a larger NAD+ rise than either alone; no toxicity is documented, and no trial has tested the combination.

  • Blood-pressure-lowering supplements (beetroot or dietary nitrate, magnesium, potassium, garlic extract, omega-3): Additive with the modest diastolic reduction from mononucleotide. Consequence is greater-than-expected pressure drop. Monitor if several are combined.

  • Trimethylglycine (betaine) and other methyl donors: Commonly co-supplemented to offset methyl-group use during nicotinamide clearance. Monitor homocysteine; the practice is mechanistically reasonable but untested in any controlled trial.

  • Resveratrol and pterostilbene: No interaction of concern, but no added benefit either — the peripheral artery disease trial found resveratrol added nothing to riboside alone. Consequence of combining is cost without demonstrated gain.

  • Alcohol: Caution — alcohol consumes NAD+ during its own metabolism and sharply intensifies nicotinic acid flushing. Consequence is severe flushing and, with heavy use, added liver strain. Separate by several hours.

Populations who should avoid NAD+:

  • People with active malignancy or a cancer diagnosis within the past five years, and anyone undergoing chemotherapy, radiotherapy or treatment with a PARP inhibitor
  • Pregnant and breastfeeding women, for whom no dosing or safety data above nutritional intake exist
  • People with liver impairment of Child-Pugh Class B or C (a liver-function grading scale), with respect to gram-dose nicotinic acid or nicotinamide above 3 g/day
  • People with poorly controlled type 2 diabetes (glycated haemoglobin above 8%) or a history of gout, with respect to the nicotinic acid route
  • People with chronic kidney disease at stage 4 or worse (estimated glomerular filtration rate below 30 mL/min/1.73 m², a measure of kidney filtering capacity), with respect to gram-level dosing
  • Anyone considering intravenous NAD+ outside a licensed medical facility with verified compounding

Risk Mitigation Strategies

  • Choose a non-flushing raw material: Selecting nicotinamide riboside, nicotinamide mononucleotide or nicotinamide over nicotinic acid removes flushing, itching and the glycaemic, hepatic, bleeding and infection excesses documented at gram doses of nicotinic acid.

  • Stay within tested doses: Riboside has controlled safety data to 1000 mg/day over eight weeks and mononucleotide to 2000 mg/day over 24 weeks. Staying inside these ranges avoids the untested territory where methyl depletion and metabolite accumulation become plausible.

  • Count total niacin equivalents: Adding up riboside, mononucleotide, nicotinamide, a B-complex and fortified foods prevents unintentionally exceeding tolerable upper intake, which drives production of the 2PY and 4PY metabolites linked to vascular inflammation.

  • Screen for cancer before starting: Age-appropriate cancer screening before beginning, and deferring use during active malignancy or PARP-inhibitor therapy, addresses the unresolved concern that added NAD+ supports tumour metabolism.

  • Dose in the morning or early afternoon: Taking the daily dose before mid-afternoon avoids the alerting effect users report with evening dosing, and matches the only timing-controlled trial, which dosed in the afternoon.

  • Check liver enzymes and glucose at 12 weeks: A baseline and 12-week panel of alanine aminotransferase, aspartate aminotransferase, fasting glucose and glycated haemoglobin catches the hepatic and glycaemic drift seen at gram-level dosing before it becomes symptomatic.

  • Use only licensed facilities for infusions: Restricting intravenous NAD+ to licensed medical settings with verified compounding, and requesting a slow infusion rate, addresses both the nausea-and-chest-pressure reaction and the preparation and sourcing failures behind reported infusion deaths.

Therapeutic Protocol

  • Nicotinamide riboside, the most-studied oral form: 250–1000 mg once daily with or without food. Whole-blood NAD+ rises dose-dependently — roughly 22%, 51% and 142% at 100, 300 and 1000 mg — and holds thereafter.

  • Nicotinamide mononucleotide, the alternative oral form: 250–900 mg once daily. Blood NAD+ and walking distance both plateau near 600 mg in dose-ranging work, so higher doses add cost rather than effect.

  • Nicotinamide, the cheap unpatented form: 500 mg twice daily is the dose used in skin-cancer chemoprevention; 1.5–3 g daily was used in glaucoma. Above 3 g daily, sirtuin inhibition and liver strain become concerns.

  • Nicotinic acid, the oldest route: 500 mg to 2 g daily raises NAD+ efficiently but carries the flushing and organ-system harms documented in large lipid trials. Practitioners focused on NAD+ generally avoid it.

  • Intravenous NAD+, the clinic approach: 250–1000 mg per session over 1–3 hours, popularised by wellness and addiction clinics rather than by trialists. No controlled outcome trial of this route exists.

  • Competing schools: Charles Brenner (advising ChromaDex, which sells riboside) argues riboside is the better-evidenced substrate; Shin-ichiro Imai and David Sinclair have championed mononucleotide. Both positions are held by parties with commercial exposure.

  • Best time of day: Morning to early afternoon. Afternoon dosing outperformed morning dosing for drowsiness and lower-limb function in the one timing-controlled trial; evening dosing is avoided because of reported alerting effects.

  • Half-life and dose splitting: Oral riboside peaks within 1–2 hours and clears within hours, but whole-blood NAD+ turns over slowly and takes about two weeks to plateau. Once-daily dosing is therefore standard; no trial has shown split dosing superior.

  • Genetic considerations: NMRK1 and NMRK2 expression governs riboside and mononucleotide activation and NAPRT governs the nicotinic acid route; NNMT activity sets clearance. None is routinely genotyped, and no pharmacogenetic dosing rule has been validated.

  • Sex-based differences: No trial has compared dosing between sexes. The insulin-sensitivity result comes from postmenopausal women only and the muscle-biopsy result from aged men only, so protocols are currently identical by default rather than by evidence.

  • Age-related considerations: Every positive functional trial enrolled adults aged roughly 55–80. Those at the older end are also the group in which the blood-pressure effect appears, and the group most likely to be taking interacting medicines.

  • Baseline biomarkers: Elevated blood pressure, prediabetic glucose or measured leg-artery disease identify the profiles in which trials found effects. Whole-blood NAD+ itself is a poor selection marker, since it does not track age reliably.

  • Pre-existing conditions: Peripheral artery disease, prediabetes, glaucoma and high-risk skin-cancer history are the settings with the strongest human evidence. Cancer, gout, diabetes and liver disease drive the avoidance list rather than the dosing choice.

Discontinuation & Cycling

  • Intended duration: Framed as indefinite rather than a course. Skin-cancer protection disappeared once nicotinamide was stopped, and blood NAD+ returns toward baseline within about two weeks of the last dose.

  • Withdrawal effects: None documented. No trial has reported rebound symptoms, and the abrupt-stop groups in crossover designs showed no adverse pattern beyond loss of the treatment effect.

  • Tapering: Not applicable to riboside, mononucleotide or nicotinamide. Gram-dose nicotinic acid is the exception: restarting after a break requires re-titration because flushing tolerance is lost within days.

  • Cycling: Not shown to help or hurt. No trial has compared continuous with intermittent dosing; the rationale offered for cycling — limiting methyl-group drain and metabolite build-up — is mechanistic rather than tested.

  • Reasons to stop: A new cancer diagnosis, the start of PARP-inhibitor therapy, unexplained liver enzyme elevation, or absence of any change in the tracked outcome after six months are the practical stopping points.

Sourcing and Quality

  • Label-claim failure is the dominant quality problem: Independent testing found only 26 of 70 nicotinamide riboside products near their stated amount, 14 of 22 mononucleotide products with none detectable, and most NAD+-labelled products on major marketplaces containing virtually none.

  • Prefer the patented, notified riboside ingredient: Niagen, ChromaDex’s crystalline riboside chloride, holds generally-recognised-as-safe status and two new-dietary-ingredient notifications, and is the form used in nearly all published trials.

  • Verify third-party testing: Look for a certificate of analysis naming the assay, plus certification from the United States Pharmacopeia, NSF International or ConsumerLab. Counterfeit Niagen has been identified in the marketplace, so buying from the brand or an authorised reseller matters.

  • Treat NAD+ itself as the wrong purchase: Capsules, patches, sprays and lozenges sold as NAD+ or NADH deliver a molecule that is degraded before absorption. The raw materials, not the finished coenzyme, are what trials used.

  • Be sceptical of liposomal and sublingual claims: Testing has found “liposomal” NAD+ products that do not deliver what their labels state, and no head-to-head trial supports sublingual mononucleotide over swallowed capsules.

  • Reputable suppliers: Tru Niagen and Life Extension for riboside, and licensed compounding pharmacies for any injectable form. Life Extension and ChromaDex both profit from the products they publish about.

Practical Considerations

  • Time to effect: Blood NAD+ rises within two weeks and then plateaus. Functional endpoints were measured at 6–12 weeks in metabolic and performance trials, at six months in the walking trial, and at twelve months in skin-cancer prevention.

  • Confusing target engagement with benefit: The commonest error is treating a higher NAD+ reading as the outcome. Blood NAD+ rises reliably in almost every trial, including those in which nothing else changed.

  • Buying the coenzyme rather than a raw material: Products labelled NAD+ or NADH are widely sold and mostly fail testing outright, so money is spent on a molecule that would not be absorbed intact even if present.

  • Stacking without counting: Combining riboside, mononucleotide, nicotinamide and a B-complex quietly pushes total intake past tolerable limits, which is where the metabolite and methyl-group concerns begin.

  • Regulatory status: Riboside holds generally-recognised-as-safe status. Mononucleotide was excluded from supplements by the US regulator in November 2022, then confirmed lawful again in September 2025 after litigation by a supplement trade association whose members sell it.

  • Cost and accessibility: Oral raw materials run roughly $30–70 per month at trial doses. Intravenous NAD+ is the exception at several hundred dollars per session and typically sold in multi-session packages, none of it covered by insurance.

  • Who pays shapes what gets studied: No insurer or health system covers any NAD+ raw material, so payers have no stake in the choice between them. Patented riboside and branded mononucleotide attract industry trials; unpatentable nicotinamide and niacin attract almost none.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. NAD+ is coupled to the circadian clock through NAMPT, whose expression oscillates daily. Afternoon dosing reduced self-rated drowsiness without altering sleep quality in the one timing-controlled trial; evening dosing is avoided because users report an alerting effect.

  • Nutrition: Direct. Tryptophan, nicotinamide and nicotinic acid from meat, fish, dairy, mushrooms and fortified grains already supply the salvage pathway, so supplements add to an existing intake. Adequate folate, choline and vitamin B12 support the methylation that clears surplus nicotinamide. Alcohol consumes NAD+ during its own breakdown.

  • Exercise: Potentiating in one direction, redundant in the other. Training raises NAMPT expression in human muscle, achieving through activity what supplements attempt through substrate. A pilot combining riboside with exercise for hypertension has been run, and rodent work found riboside blunted endurance performance rather than improving it.

  • Stress management: Indirect. Psychological and oxidative stress drive DNA damage and inflammation, which activate PARP enzymes and CD38 to consume NAD+. Lowering that load reduces demand rather than raising supply. No trial has measured cortisol or stress-axis outcomes with any NAD+ raw material.

Monitoring Protocol & Defining Success

Baseline testing serves two purposes: establishing the outcomes worth tracking, and excluding the conditions under which raising NAD+ carries added risk. Before starting, seated blood pressure, a fasting metabolic panel with glucose and glycated haemoglobin, liver enzymes, kidney function, uric acid, high-sensitivity C-reactive protein and a lipid panel establish the picture, alongside age-appropriate cancer screening. A functional baseline — six-minute walk distance or a timed chair-stand — anchors the performance claims that motivate most use.

Ongoing monitoring is light because oral raw materials at tested doses have not moved laboratory markers. A reasonable cadence is a repeat panel at 12 weeks, then every 6–12 months. Gram-dose nicotinic acid warrants tighter follow-up, at 6 and 12 weeks and then every 3–6 months, because its harms accumulate in glucose control, liver enzymes and uric acid.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Seated blood pressure 110–120 / 70–75 mmHg The one endpoint with replicated benefit Average three readings after five minutes seated; conventional treatment threshold is 130/80 mmHg
Whole-blood NAD+ No established target; track change from the individual’s own baseline Confirms the product is absorbed and active Specialist assay only; does not track age reliably, so it shows engagement, not benefit
Fasting glucose 75–86 mg/dL (4.2–4.8 mmol/L) Detects the glycaemic drift seen with gram-dose nicotinic acid 12-hour fast; conventional cut-off of 100 mg/dL is far above the functional target
Glycated haemoglobin (HbA1c) 4.8–5.2% Confirms glucose control over months, not a single morning HbA1c is average blood sugar over roughly three months; conventional normal runs to 5.6%, with 5.7–6.4% labelled prediabetes; no fasting needed; pair with fasting insulin; unreliable in anaemia or after recent blood loss
Alanine and aspartate aminotransferase (ALT, AST) 10–26 U/L (both) Catches hepatic strain at gram-level dosing ALT and AST are liver enzymes released when liver cells are stressed; conventional upper limits near 40–55 U/L are far more permissive; avoid intense exercise for 48 hours beforehand
Uric acid 3.5–5.5 mg/dL Nicotinic acid competes with urate for renal excretion and can trigger gout Fasting draw; conventional upper limit is 7.0 mg/dL
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Inflammation drives NAD+ consumption, so it frames expected benefit hs-CRP is a general marker of systemic inflammation; conventional low-risk cut-off is anything below 1.0 mg/L; postpone for two weeks after any infection or injury; pair with a full blood count
Estimated glomerular filtration rate (eGFR) and creatinine eGFR above 90 mL/min/1.73 m² Screens for the kidney disease that changes the risk calculus eGFR estimates kidney filtering capacity; conventional normal starts at 60 mL/min/1.73 m²; cystatin C gives a better estimate in people with high muscle mass
Homocysteine 5–7 µmol/L Reflects methyl-group availability, which clearing surplus nicotinamide consumes Conventional upper limit is around 15 µmol/L, far above the functional target; fasting draw, processed promptly; interpret with folate and vitamin B12
Lipid panel with LDL and HDL cholesterol LDL below 100 mg/dL; HDL above 50 mg/dL Relevant only on the nicotinic acid route, which shifts both LDL and HDL are low- and high-density lipoprotein, the main cholesterol-carrying particles; 12-hour fast preferred; unchanged by riboside or mononucleotide

Qualitative markers worth tracking alongside the laboratory panel:

  • Sustained daytime energy, and whether it fades if dosing is paused for two weeks
  • Afternoon drowsiness and self-rated fatigue, the endpoint that moved in the timing-controlled trial
  • Sleep onset latency and night-time waking, particularly if the dose drifts later in the day
  • Exercise recovery and perceived effort on familiar sessions
  • Walking distance or stair tolerance, for those using it for leg-artery symptoms
  • Flushing, nausea or bloating in the first fortnight, which usually indicate the form or dose rather than intolerance to NAD+ itself

Emerging Research

  • Frailty and gait speed: The NADage trial (NCT06208527) randomises 100 frail older adults to nicotinamide riboside or placebo, with between-group change in gait speed as the primary endpoint and completion due 2030. It is the first trial to target frailty itself.

  • Atypical parkinsonism: NADAPT (NCT06162013) is a 330-participant phase 2 trial across progressive supranuclear palsy, multiple system atrophy and corticobasal syndrome (three rare, fast-moving brain diseases that resemble Parkinson’s), measuring disease-rating-scale change at 78 weeks. It follows the earlier phase 1 NADPARK study in Parkinson’s disease.

  • Progressive multiple sclerosis: A 300-participant phase 2 trial (NCT05740722) tests whether riboside slows sustained disability progression, with completion due 2027. A positive result would be the first hard neurological endpoint for any NAD+ raw material.

  • Confirmation in peripheral artery disease: NICE-PAD II (NCT07782671) is a 250-participant phase 3 trial powered to confirm or refute the walking-distance gain seen in the smaller NICE trial. It is the single most consequential trial for the current benefit case.

  • Brain blood flow in ageing: A 214-participant phase 4 trial (NCT05483465) measures neurovascular coupling — how blood flow follows neural activity — after NAD+ supplementation, directly addressing the reduced default-mode blood flow reported by Orr et al., 2024.

  • Whether the founding premise holds: Trętowicz et al., 2026 found whole-blood NAD+ stable across age and lifestyle in seven cohorts, and Vinten et al., 2025 argue the tissue evidence is sparse. Tissue-level measurement is the research direction that could undercut the entire rationale.

  • Long-term cancer surveillance: No trial tracks cancer incidence in users, leaving the concern raised by Maric et al., 2023 unresolved. Registry linkage or extended follow-up of existing trial cohorts is the realistic path to an answer.

  • Metabolite-driven cardiovascular risk: Whether the pyridone metabolites linked to heart events by Ferrell et al., 2024 accumulate at riboside and mononucleotide doses is untested. Measuring them inside existing trials would be inexpensive and could weaken the safety case.

Conclusion

NAD+ is a molecule every cell depends on for energy production and DNA repair, and cells cannot absorb it directly, so raising it means taking one of its raw materials — most often nicotinamide riboside or nicotinamide mononucleotide, sometimes the older and cheaper forms of vitamin B3, occasionally an infusion.

Those raw materials do what they should at the chemical level: blood NAD+ rises reliably and holds. What follows is far less certain. The clearest human benefits are a small drop in the lower blood-pressure number in older people with raised readings, fewer new skin cancers in those already prone to them, better walking distance in narrowed leg arteries, and better muscle sugar handling before diabetes sets in. Muscle strength, thinking ability and lifespan have not followed.

On the harm side, the swallowed forms have been well tolerated for up to six months, with no excess side effects over placebo. The older gram-dose form of vitamin B3 is a different matter, with documented harm across several organ systems. Infusions carry the poorest oversight and have been linked to deaths. Longer-term questions — whether extra supply feeds an existing cancer, and whether the breakdown products inflame blood vessels — stay open.

Much of the supporting evidence comes from the companies selling these products, and the regulatory reversal that returned one form to the shelves followed pressure from a trade body whose members sell it. The starting assumption that NAD+ falls with age is itself now contested.

Top - Benefits - Risks - Protocol